Promimic AB is a Sweden-based biomaterial company. The Company manufactures, markets and sells biomaterials for improved osseointegration (bone healing) to the companies in the markets for orthopedic and dental implants. The Company operates primarily in the United States, Europe, and South America, with current product applications in the dental, spine, total joint, extremities, and sports medicine implant markets.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
17/07/26	SEK 10.40	+2.97%	1,004
16/07/26	SEK 10.10	+2.02%	5,992
15/07/26	SEK 9.900	-1.98%	191
14/07/26	SEK 10.10	-1.94%	3,161
13/07/26	SEK 10.30	0.00%	356

Delayed Quote Nasdaq Stockholm

More quotes

Income Statement and Estimates

More financial data

Market Closed - Nasdaq Stockholm Other stock markets 17:00:00 17/07/2026 BST			5-day change	1st Jan Change
10.40 ^SEK	+2.97%		+0.97%	-38.64%

05-19	Promimic Q1 2026 operating loss at SEK 3.5 mln	RE
05-19	Promimic AB Reports Earnings Results for the First Quarter Ended March 31, 2026	CI

Market Cap	196M 20.38M 17.81M 16.44M 15.15M 28.56M 1.96B 29.19M 77.28M 961M 76.55M 74.87M 3.31B	P/E 2024	-33.7x	P/E 2025	-36.6x
Enterprise Value	176M 18.24M 15.94M 14.71M 13.56M 25.56M 1.76B 26.13M 69.17M 860M 68.52M 67.01M 2.96B	EV / Sales 2024	7.85x	EV / Sales 2025	5.87x
Free-Float	14.76%	Yield 2024 *	-	Yield 2025	-

05-19	Promimic Q1 2026 operating loss at SEK 3.5 mln	RE
05-19	Promimic AB Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-16	Promimic nomination committee proposes new chairman	RE
02-24	Promimic Q4 net sales SEK 11.5 mln	RE
02-24	Promimic AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025	CI
11-19	Promimic Q3 sales of SEK 12.9 mln	RE
11-19	Promimic AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
22/08/25	Promimic AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
11/06/25	Promimic's CFO Heidi Bader makes a minor share purchase	FW
15/05/25	Promimic reports slightly lower operating loss	FW
15/05/25	Promimic Q1 Sales Increase 1.4% To 8.8 Msek	RE
15/05/25	Promimic AB Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
05/05/25	Promimic deepens collaboration with Curiteva	FW

1 day	+2.97%
1 week	+0.97%
Current month	+4.00%
3 months	-0.95%
6 months	-29.01%
Current year	-38.64%

Promimic AB Share Price

Stocks

PRO

SE0017487242

Biotechnology & Medical Research

Valuation: Promimic AB

Chart: Promimic AB

Latest news : Promimic AB

Analysts' recommendations: Promimic AB

Press Releases: Promimic AB

Quotes and Performance

Course Extremes

Managers and Directors: Promimic AB

Latest insider transactions

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Income Statement and Estimates

1 week	9.9	11.4
1 month	9.75	12
Current year	8.14	16.55
1 year	8.14	20.5
3 years	8.14	45
5 years	8.14	45
10 years	8.14	45

Manager	Title	Age	Since
Per Gunnar Kjellin CTO	Chief Tech/Sci/R&D Officer	54	31/12/2003
Magnus Larsson CEO	Chief Executive Officer	63	17/01/2017
Heidi Bader DFI	Director of Finance/CFO	45	31/12/2022

Director	Title	Age	Since
Helena Maria Brisby BRD	Director/Board Member	61	31/12/2020
Johan Dighed BRD	Director/Board Member	53	31/12/2020
Pehr Abrahamsson BRD	Director/Board Member	59	31/12/2020

Date	Insider	Type	Main position	Quantity	% Market Cap.
11/10/24	Magnus Larsson	Fiscal year	Chief Executive Officer	160,000	0.8685%
11/10/24	Magnus Larsson	Fiscal year	Chief Executive Officer	16,000	0.0869%
11/10/24	Magnus Larsson	Sell	Chief Executive Officer	125,000	0.6785%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
PROMIMIC AB	+2.97%	+0.97%	-39.36%	-64.63%	20.38M
REVOLUTION MEDICINES, INC.	+3.90%	-0.39%	+376.72%	+599.59%	39.58B
BEONE MEDICINES AG	-1.70%	+4.46%	+7.46%	+57.67%	34.69B
IQVIA HOLDINGS INC.	-2.01%	-0.76%	+26.35%	-6.83%	34.42B
CELLTRION, INC.	+0.06%	+0.34%	+2.32%	+29.30%	27.11B
ASCENDIS PHARMA A/S	+0.46%	-3.49%	-	-	16.21B
MEDPACE HOLDINGS, INC.	-0.04%	-0.09%	+68.48%	+117.39%	15.36B
EUROFINS SCIENTIFIC SE	+1.12%	+1.91%	+15.90%	+19.65%	14.05B
ICON PUBLIC LIMITED COMPANY	0.00%	+1.36%	+15.74%	-30.62%	13.02B
ABIVAX	-0.08%	-3.01%	+1,271.69%	+649.69%	11.76B
Average	+0.47%	+0.13%	+193.92%	+152.35%	20.62B
Weighted average by Cap.	+0.24%	+0.36%	+171.41%	+187.39%

	2024	2025
Net sales	48.91M 5.07M 4.43M 4.09M 3.77M 7.11M 489M 7.27M 19.24M 239M 19.06M 18.64M 824M	51.06M 5.3M 4.63M 4.27M 3.94M 7.42M 510M 7.59M 20.08M 250M 19.89M 19.46M 860M
Net income	-12.55M -1.3M -1.14M -1.05M -968K -1.82M -125M -1.86M -4.94M -61.41M -4.89M -4.78M -211M	-8.75M -908K -794K -732K -675K -1.27M -87.46M -1.3M -3.44M -42.84M -3.41M -3.34M -147M
Net Debt	-35.76M -3.71M -3.24M -2.99M -2.76M -5.2M -357M -5.31M -14.07M -175M -13.94M -13.63M -602M	-20.63M -2.14M -1.87M -1.73M -1.59M -3M -206M -3.07M -8.11M -101M -8.04M -7.86M -348M